Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FDA Approves Lirafugratinib for FGFR2+ Cholangiocarcinoma

5 October 2026 · By · Wire by Fusion42

Published

5 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at clinicaloncology.com →

◆ Verified

Fusion42 · 5 October 2026 · Fusion42 review

The FDA has approved lirafugratinib for the treatment of FGFR2-positive cholangiocarcinoma, marking a regulatory milestone for targeted cancer therapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 16 Sep 2026 and 5 Oct 2026.

◆ ◆ The Wire takeaway

You can now access a regulatory route in US oncology markets focusing on rare liver cancers, making it viable to develop FGFR2-targeted molecules for cholangiocarcinoma.

◆ Coverage

10 sources · first reported 16 Sep 2026 · latest 5 Oct 2026

◆ Topics

BiotechFDA-approvalcholangiocarcinomaFGFR2targeted-therapy